New hope for hard-to-treat lymphoma: drug cocktail shows promise

NCT ID NCT05364424

First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 33 times

Summary

This early-phase study tested a new drug combination for people with a fast-growing lymphoma (DLBCL) that returned after initial treatment. The study included 43 adults who were healthy enough for a stem cell transplant or CAR-T therapy. They received the experimental drug glofitamab alongside standard chemotherapy to see if the combination could shrink tumors and how safe it was.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Chao Family Comprehensive Cancer Center UCI

    Orange, California, 92868, United States

  • Cleveland Clinic Foundation

    Cleveland, Ohio, 44195, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Memorial Cancer Institute at Memorial West

    Pembroke Pines, Florida, 33028, United States

  • New York University Langone Medical Center

    New York, New York, 10016, United States

  • The University of Chicago

    Chicago, Illinois, 60637, United States

  • Tulane Medical Center

    New Orleans, Louisiana, 70112, United States

  • UMASS Memorial Medical Center

    Worcester, Massachusetts, 01655, United States

Conditions

Explore the condition pages connected to this study.